Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans‐Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise

Variation in target volume delineation from clinical trial protocols has been shown to contribute to poorer patient outcomes. A clinical trial quality assurance framework can support compliance with trial protocol. Results of the TROG 08.03 RAVES benchmarking exercise considering variation from protocol, inter‐observer variability and impact on dosimetry are reported in this paper.

[1]  Tom Vercauteren,et al.  Delineation of the postprostatectomy prostate bed using computed tomography: interobserver variability following the EORTC delineation guidelines. , 2011, International journal of radiation oncology, biology, physics.

[2]  C. Njeh,et al.  Tumor delineation: The weakest link in the search for accuracy in radiotherapy , 2008, Journal of medical physics.

[3]  R. Fisher,et al.  A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high‐risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial , 2014, BJU international.

[4]  L. Holloway,et al.  Uncertainties in volume delineation in radiation oncology: A systematic review and recommendations for future studies. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  International Commission on Radiation Units and Measurements , 2019 .

[6]  R. Cowan,et al.  Assessing the effect of a contouring protocol on postprostatectomy radiotherapy clinical target volumes and interphysician variation. , 2009, International journal of radiation oncology, biology, physics.

[7]  D. Followill,et al.  Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review. , 2013, International journal of radiation oncology, biology, physics.

[8]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[9]  Jean-Yves Giraud,et al.  Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Michael G Jameson,et al.  A review of methods of analysis in contouring studies for radiation oncology , 2010, Journal of medical imaging and radiation oncology.

[11]  Brian O'Sullivan,et al.  Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Michel Bolla,et al.  Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Allan Hanbury,et al.  Metrics for evaluating 3D medical image segmentation: analysis, selection, and tool , 2015, BMC Medical Imaging.

[14]  Jennifer Croke,et al.  Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT. , 2012, International journal of radiation oncology, biology, physics.

[15]  Damien C Weber,et al.  QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  C. Hess,et al.  The Impact of Gross Tumor Volume (GTV) and Clinical Target Volume (CTV) Definition on the Total Accuracy in Radiotherapy , 2003, Strahlentherapie und Onkologie.

[17]  Annette Haworth,et al.  A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  William M. Wells,et al.  Simultaneous truth and performance level estimation (STAPLE): an algorithm for the validation of image segmentation , 2004, IEEE Transactions on Medical Imaging.

[19]  Adam P Dicker,et al.  Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. , 2013, Journal of the National Cancer Institute.

[20]  Li Tee Tan,et al.  Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials , 2017, Front. Oncol..

[21]  Walter J Curran,et al.  Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. , 2012, International journal of radiation oncology, biology, physics.

[22]  Masoom A Haider,et al.  Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. , 2007, International journal of radiation oncology, biology, physics.

[23]  Jeremy L Millar,et al.  Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  P. Manser,et al.  Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10. , 2013, International journal of radiation oncology, biology, physics.

[25]  Michel Bolla,et al.  Quality assurance of the EORTC 22043-30041 trial in post-operative radiotherapy in prostate cancer: results of the Dummy Run procedure. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  P. Metcalfe,et al.  Results of the Australasian (Trans‐Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC‐3 trial , 2016, Journal of medical imaging and radiation oncology.

[27]  Issam El Naqa,et al.  Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. , 2010, International journal of radiation oncology, biology, physics.

[28]  D. Followill,et al.  Quality Assurance for Clinical Trials , 2013, Front. Oncol..

[29]  M. Tomsej,et al.  Quality assurance for the EORTC 22071–26071 study: dummy run prospective analysis , 2014, Radiation oncology.

[30]  Tomas Kron,et al.  Radiation therapy quality assurance in clinical trials--Global Harmonisation Group. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  N. Spry,et al.  Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.